Trial Profile
Clinical Trials Insight: 700038430
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2008
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Antineoplastics
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Cell Therapeutics
- 29 Oct 2008 New trial record.